These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4348906)

  • 1. [Morphology and biochemistry of Parkinson's syndrome].
    Jellinger K
    Cesk Patol; 1973 Feb; 9(1):1-13. PubMed ID: 4348906
    [No Abstract]   [Full Text] [Related]  

  • 2. The metabolism of brain dopamine in human parkinsonism.
    Hornykiewicz O
    Riv Patol Nerv Ment; 1970 Oct; 91(5):281-6. PubMed ID: 5525774
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.
    Fahn S; Libsch LR; Cutler RW
    J Neurol Sci; 1971 Dec; 14(4):427-55. PubMed ID: 5125758
    [No Abstract]   [Full Text] [Related]  

  • 4. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced changes in brain dopamine and their relation to parkinsonism.
    Vogt M
    Sci Basis Med Annu Rev; 1970; ():276-91. PubMed ID: 4319923
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
    Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F
    J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
    Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
    Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 12. The Lewy body in Parkinson's disease.
    Forno LS
    Adv Neurol; 1987; 45():35-43. PubMed ID: 3030070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V
    Arch Neurol; 1973 Feb; 28(2):107-10. PubMed ID: 4683147
    [No Abstract]   [Full Text] [Related]  

  • 14. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkin implicated in sporadic Parkinson's disease.
    Pilcher H
    Lancet Neurol; 2005 Dec; 4(12):798. PubMed ID: 16323352
    [No Abstract]   [Full Text] [Related]  

  • 16. Commentary: olfactory dysfunction in Parkinson's disease.
    Li J; Cui Y; Yuan TF; Arias-Carrion O
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1079-80. PubMed ID: 24392859
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain acetylcholinesterase in Parkinson's disease.
    Rinne UK; Riekkinen P; Sonninen V; Laaksonen H
    Acta Neurol Scand; 1973; 49(2):215-26. PubMed ID: 4718190
    [No Abstract]   [Full Text] [Related]  

  • 18. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
    Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
    Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental midbrain lesions: neurochemical comparison between the animal model and Parkinson's disease.
    Hockman CH; Lloyd KG; Farley IJ; Hornykiewicz O
    Brain Res; 1971 Dec; 35(2):613-8. PubMed ID: 5135560
    [No Abstract]   [Full Text] [Related]  

  • 20. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease.
    Attems J; Jellinger KA
    Neuropathol Appl Neurobiol; 2008 Aug; 34(4):466-7. PubMed ID: 18282157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.